This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

MorphoSys Toekomstige groei

Future criteriumcontroles 2/6

MorphoSys is forecast to grow earnings and revenue by 59.1% and 25% per annum respectively. EPS is expected to grow by 78.2% per annum. Return on equity is forecast to be 7.7% in 3 years.

Belangrijke informatie

59.1%

Groei van de winst

78.2%

Groei van de winst per aandeel

Biotechs winstgroei	28.6%
Inkomstengroei	25.0%
Toekomstig rendement op eigen vermogen	7.7%
Dekking van analisten	Good
Laatst bijgewerkt	05 Aug 2024

Recente toekomstige groei-updates

Recent updates

Winst- en omzetgroeiprognoses

NasdaqGS:MOR - Toekomstschattingen van analisten en financiële gegevens uit het verleden (EUR Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	425	-78	-120	-50	5
12/31/2025	322	-140	-236	-201	8
12/31/2024	180	-249	-296	-253	3
3/31/2024	241	-469	-286	-284	N/A
12/31/2023	238	-190	-299	-296	N/A
9/30/2023	223	104	-363	-355	N/A
6/30/2023	255	100	-349	-338	N/A
3/31/2023	261	-61	-321	-306	N/A
12/31/2022	278	-151	-382	-367	N/A
9/30/2022	250	-861	-436	-417	N/A
6/30/2022	195	-851	-606	-588	N/A
3/31/2022	174	-596	-610	-583	N/A
12/31/2021	180	-514	-508	-481	N/A
9/30/2021	163	-150	-423	-393	N/A
6/30/2021	143	-103	-295	-246	N/A
3/31/2021	124	-177	-255	-217	N/A
12/31/2020	328	98	-14	35	N/A
9/30/2020	303	64	26	63	N/A
6/30/2020	293	105	98	113	N/A
3/31/2020	309	153	137	152	N/A
12/31/2019	72	-103	-85	-81	N/A
9/30/2019	71	-96	-68	-64	N/A
6/30/2019	114	-42	-42	-39	N/A
3/31/2019	87	-59	-33	-31	N/A
12/31/2018	76	-56	-35	-33	N/A
9/30/2018	94	-27	-16	-14	N/A
6/30/2018	54	-82	-61	-48	N/A
3/31/2018	58	-74	-68	-55	N/A
12/31/2017	67	-70	N/A	-38	N/A
9/30/2017	52	-84	N/A	-52	N/A
6/30/2017	49	-73	N/A	-59	N/A
3/31/2017	49	-68	N/A	-47	N/A
12/31/2016	50	-60	N/A	-47	N/A
9/30/2016	49	-45	N/A	-48	N/A
6/30/2016	48	-40	N/A	-41	N/A
3/31/2016	48	-33	N/A	-35	N/A
12/31/2015	106	15	N/A	-24	N/A
9/30/2015	111	27	N/A	-15	N/A
6/30/2015	116	33	N/A	-3	N/A
3/31/2015	119	37	N/A	-4	N/A
12/31/2014	64	-3	N/A	-14	N/A
9/30/2014	61	-6	N/A	-15	N/A
6/30/2014	60	-5	N/A	79	N/A
3/31/2014	77	7	N/A	76	N/A
12/31/2013	78	7	N/A	89	N/A
9/30/2013	80	14	N/A	100	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: MOR is forecast to remain unprofitable over the next 3 years.

Winst versus markt: MOR is forecast to remain unprofitable over the next 3 years.

Hoge groeiwinsten: MOR is forecast to remain unprofitable over the next 3 years.

Omzet versus markt: MOR's revenue (25% per year) is forecast to grow faster than the US market (8.5% per year).

Hoge groei-inkomsten: MOR's revenue (25% per year) is forecast to grow faster than 20% per year.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: MOR's Return on Equity is forecast to be low in 3 years time (7.7%).

This company listing is no longer active

MorphoSys Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

MorphoSys AG Provides Sales Guidance for the Financial Year 2024

Morphosys AG Provides Earnings Guidance for the Year 2023

MorphoSys AG Provides Earnings Guidance for the Year 2023

Morphosys Ag Provides Sales Guidance for the Financial Year 2023

Morphosys Ag Revises Monjuvi U.S. Net Product Sales Guidance for the Full Year of 2022

Morphosys Ag Updates Monjuvi U.S. Net Product Sales Guidance for the Year 2022

Recent updates

MorphoSys Completes Voluntary Delisting from the Frankfurt Stock Exchange and Nasdaq Global Market

MorphoSys AG, Annual General Meeting, Aug 27, 2024

MorphoSys Announces Voluntary Delisting from the Nasdaq Global Market

MorphoSys AG to Report Q2, 2024 Results on Aug 29, 2024

MorphoSys AG(XTRA:MOR) dropped from Germany MDAX Index (Performance)

MorphoSys AG(XTRA:MOR) dropped from Germany TECDAX (Total Return) Index

MorphoSys AG Announces Board Changes

Novartis Continues to Progress the Workstreams for Implementation of a Delisting of MorphoSys

Novartis Continues to Progress the Workstreams for Implementation of a Delisting of MorphoSys

MorphoSys: Hold Rating Until The Novartis Deal Closes

Novartis data42 AG entered into an agreement to make a voluntary public takeover offer to acquire MorphoSys AG (XTRA:MOR) for €2.3 billion.

Novartis data42 AG entered into an agreement to make a voluntary public takeover offer to acquire MorphoSys AG (XTRA:MOR) for €2.3 billion.

Novartis And MorphoSys Are A Perfect Match

Novartis Reportedly in Lead to Acquire MorphoSys

MorphoSys AG Provides Sales Guidance for the Financial Year 2024

MorphoSys: Positive Pelabresib Data Finally Unlocking Upside

MorphoSys AG to Report First Half, 2024 Results on Aug 07, 2024

MorphoSys AG has filed a Follow-on Equity Offering in the amount of €102.69582 million.

MorphoSys AG to Report Fiscal Year 2023 Results on Mar 13, 2024

MorphoSys AG’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study

MorphoSys AG Announces Strong Topline Results from the Phase 3 MANIFEST-2 Study Investigating Pelabresib

MorphoSys AG to Showcase Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2023 ASH Annual Meeting

Morphosys AG Provides Earnings Guidance for the Year 2023

Zoetis Inc. (NYSE:ZTS) acquired adivo GmbH from founders, High-Tech Gründerfonds, the Swiss Occident Group AG and MorphoSys AG (XTRA:MOR).

MorphoSys Receives U.S. FDA Fast Track Designation for Tulmimetostat in Endometrial Cancer

MorphoSys AG Provides Earnings Guidance for the Year 2023

Morphosys Ag Provides Sales Guidance for the Financial Year 2023

MorphoSys AG Expects Topline Data from Phase 3 Study of Pelabresib in Myelofibrosis in Early 2024

MorphoSys AG Announces Sung Lee, Chief Financial Officer Decided to Leave

Morphosys Presents New Longer-Term Phase 2 Results on Pelabresib in Myelofibrosis, Including Potential Disease-Modifying Activity At Ash 2022

MorphoSys AG to Report Q3, 2023 Results on Nov 15, 2023

MorphoSys AG Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat (CPI-0209)

Morphosys Ag Revises Monjuvi U.S. Net Product Sales Guidance for the Full Year of 2022

MorphoSys AG Announces Executive Changes

Morphosys Ag Updates Monjuvi U.S. Net Product Sales Guidance for the Year 2022

MorphoSys updates Q2 & FY22 guidance below prior provided levels

MorphoSys AG Confirms Financial Guidance for the Year 2022

MorphoSys AG Announces Supervisory Board Changes

MorphoSys May Not Recover From Adventurous Constellation Buyout

Sierra Oncology's Strong Data In Myelofibrosis Challenges MorphoSys And Incyte

MorphoSys Presents Latest Data from the Phase 2 Manifest Study Evaluating the Potential of Pelabresib in the Treatment of Myelofibrosis

MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi®) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Health Canada Grants Marketing Authorization for Minjuvi® (Tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

MorphoSys AG (XTRA:MOR) completed the acquisition of Constellation Pharmaceuticals, Inc. (NasdaqGS:CNST).

Incyte and MorphoSys Announce Positive CHMP Opinion for Tafasitamab in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Incyte and MorphoSys presents new three-year data for blood cancer therapy

MorphoSys to Present Data on Tafasitamab (Monjuvi(R)) at the 2021 ASCO Annual Meeting

Incyte and MorphoSys Announce First Patient Dosed in Phase 3 frontMIND Study Evaluating Tafasitamab Combination as a First-Line Treatment for Diffuse Large B-Cell Lymphoma

MorphoSys AG Reaffirms Group Financial Guidance for the Year 2021

MorphoSys reports Q1 results

I-Mab and MorphoSys Announce First Patient Dosed in U.S. Phase 1 Study of TJ210/MOR210 in Patients with Advanced Cancer

Incyte Corporation and MorphoSys AG Announce Acceptance by Health Canada of the New Drug Submission for Tafasitamab

MorphoSys AG Announces Management Changes

MorphoSys AG appoints Sangamo 's Sung Lee as new CFO

Morphosys and Incyte Announce the Acceptance of the Swissmedic Marketing Authorization Application for Tafasitamab

MorphoSys AG, Annual General Meeting, May 19, 2021

Incyte and MorphoSys AG Announces Data Evaluating Tafasitamab with and Without Lenalidomide in Combination with R-CHOP in Patients with DLBCL Presented At ASH 2020

MorphoSys AG (MOR) Investor Presentation - Slideshow

Morphosys' Licensee Announces Approval by the European Commission for Tremfya(R) (Guselkumab) for Treatment of Adults with Active Psoriatic Arthritis

MorphoSys Appoints Thomas Biegi as Vice President, Head of Corporate Communications

MorphoSys AG 2020 Q3 - Results - Earnings Call Presentation

Xencor, MorphoSys AG and Incyte Enter into Global Development Collaboration for Tafasitamab in Combination with Plamotamab

MorphoSys reports Q3 results

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven